To visit the old Ventura website, click here.
Ventura Wealth Clients Login here
Refer and earnSupport
logosearch
Create Account
hamburger
home
breadcrumbStocks
breadcrumbEris Lifesciences Ltd Share Price
breadcrumbResults

Quarterly results

rupeeShow figures in :
rupeeShow figures in :

Quarterly results

Quarter ended on March 31, 2025Data in Crores of INR
Revenue
₹ 705.30+28.02% from last year
Operating profits
₹ 260.34+59.15% from last year
Net income
₹ 102.29+28.45% from last year

Financial reports

Data is unavailable

INCOME STATEMENTinfo2
Data in Crores of INR

Data is unavailable

BALANCE SHEETinfo2
Data in Crores of INR
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Net worth2854.362586.182195.991908.311576.421296.331150.52861.31567.14299.62
Fixed assets5306.484319.162568.10917.94853.87874.85760.54771.09231.6571.37
Debt2421.662735.27830.0245.010.01-176.42376.800.650.50
docView detailed balance sheet
arrow
CASH FLOWinfo2
Data in Crores of INR
FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating1065.01486.01291.74378.26375.36271.17223.00234.64200.21131.48
Investing -79.97-1854.52-982.10-319.61-323.36123.23-5.05-590.10-184.46-43.91
Financing -881.321379.68688.03-44.70-82.40-334.59-221.05363.21-23.66-83.70

Financial ratios

Profitability ratiosinfo2
ROA5.48%
ROE13.81%
ROCE13.59%
EPS25.83%
Net profit margin12.95%
Operating profit margin34.84%
Dividend per share7.35%
Operational ratiosinfo2
Quick ratio0.67%
Current ratio0.89%
Interest coverage3.11%
Assets turnover0.43%
Debt to equity0.85%
Valuation ratiosinfo2
P/E ratio68.28%
P/B ratio8.45%
Dividend yield0.42%
EV/EBITDA
Eris Lifesciences Limited founded by Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.
personal

Grow your wealth with more research recommendations

+91